30 closest matches · ranked by relevance
Cholangiocarcinoma · Stage III Gallbladder Cancer AJCC v7 · Stage IIIA Gallbladder Cancer AJCC v7
Primary: 16-Week Progression-free Survival (PFS) Rate — 32.0 percentage of patients
Stage III Distal Bile Duct Cancer AJCC v8 · Stage III Gallbladder Cancer AJCC v8 · Stage III Intrahepatic Cholangiocarcinoma AJCC v8
Primary: Overall Survival (OS) — 14.0; 13.6 months — p=0.41
Extrahepatic Bile Duct Cancer · Gallbladder Cancer
Primary: Progression-Free Survival — 51 percentage of participants
Advanced Bile Duct Carcinoma · Advanced Gallbladder Carcinoma · Refractory Bile Duct Carcinoma
Primary: Progression-free Survival (PFS) — 37.0 percentage of participants
Biliary Tract Cancer · Biliary Tract Neoplasms
Primary: Overall Response Rate (ORR) After 4 Cycles of Treatment — 22 percent
Advanced Biliary Tract Carcinoma
Primary: MTD of MEK162 - Phase I — 45 mg
Cholangiocarcinoma of the Extrahepatic Bile Duct · Cholangiocarcinoma of the Gallbladder · Gastrointestinal Cancer
Primary: Number of Confirmed Tumor Responses. — 6; 0 participants
Biliary Cancer · Cholangiocarcinoma
Primary: Progression Free Survival Rate at Five Months — 69 percentage of participants
Adenocarcinoma
Primary: Progression-free Survival (PFS) — 91; 148 days
Biliary Tract Cancer · Cholangiocarcinoma · Gallbladder Cancer
Primary: Percentage of Participants With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by…
Biliary Tract Cancer · Gallbladder Cancer · Cancer Of The Extrahepatic Bile Duct
Primary: Progression Free Survival — 105; 114; 148 days
Cholangiocarcinoma · Liver and Intrahepatic Bile Duct Carcinoma · Stage III Gallbladder Cancer AJCC v7
Primary: Progression Free Survival of Ramucirumab in Advanced Biliary Cancers — 3.2 months
Stage III Intrahepatic Cholangiocarcinoma AJCC v7 · Stage IIIA Gallbladder Cancer AJCC v7 · Stage IIIB Gallbladder Cancer AJCC v7
Primary: Median Progression Free Survival (PFS) — 11.4; 14.9 months — p=0.62
Biliary Tract Neoplasms
Primary: The Percentage of Patients Alive and Without Progression at 6 Months Following the Initiation of Treatment — 59.4; 21.2 percentage of participants
Metastatic Biliary Tract Carcinoma
Primary: Progression-free Survival (PFS) — 3.58 months
Extrahepatic Bile Duct Cancer · Gallbladder Cancer
Primary: Stratum-specific (R0 and R1) 2-year Overall Survival — 67; 60 percentage of participants
Extrahepatic Bile Duct Adenocarcinoma · Gallbladder Adenocarcinoma · Gallbladder Adenocarcinoma With Squamous Metaplasia
Primary: Progression-free Survival — 2 months
Advanced Adult Hepatocellular Carcinoma · Localized Non-Resectable Adult Liver Carcinoma · Recurrent Adult Liver Carcinoma
Primary: Overall Response Rate (Complete and Partial Response) as Defined by RECIST 1.1 — 0 patients
Biliary Tract Cancer
Primary: Phase Ib: Incidence of Dose-limiting Toxicities (DLTs) of Drug Combination Nanoliposomal-Irinotecan, 5-fluorouracil, Leucovorin and Nivolumab — 4 Participants
Bile Duct Cancer · Intrahepatic Cholangiocarcinoma · Cholangiocarcinoma of the Extrahepatic Bile Duct
Primary: Median Progression Free Survival (PFS) — 1.8 months
Cancer of the Bile Duct
Primary: Overall Survival (OS) at 6 Months — 7.9 months
Adult Primary Cholangiocellular Carcinoma · Advanced Adult Primary Liver Cancer · Cholangiocarcinoma of the Extrahepatic Bile Duct
Primary: Overall Survival — 4.7; 1.6; 3.94 months
Biliary Tract Cancer · Gallbladder Cancer
Primary: The Number of Participants With Response to GEMOX-Panitumumab (GEMOX-P) in Chemotherapy naïve KRAS/ BRAF Wild Type Stage IV Biliary Tract Cancer Using the Response…
Biliary Tract Neoplasms · Cholangiocarcinoma · Bile Duct Cancer
Primary: Progression Free Survival (PFS) — 4.54 Months
Adult Cholangiocarcinoma · Advanced Adult Hepatocellular Carcinoma · BCLC Stage C Adult Hepatocellular Carcinoma
Primary: Overall Survival — 4.3; 7.9 months — p=0.05
Biliary Tract Cancer
Primary: Percentage of Patients Alive at 1 Year (1-Year Survival Rate) — 39; 31 percentage of participants
Biliary Tract Cancer
Primary: Progression Free Survival (PFS) — 7.92; 8.35 Months
Biliary Tract Cancer
Primary: Objective Response Rate (ORR) - Part 1 — 0; 0; 6; 3 Participants
Extrahepatic Bile Duct Cancer · Gallbladder Cancer
Primary: Response — 7; 6; 12; 15 participants
HER2-amplified Biliary Tract Cancers
Primary: Confirmed Objective Response Rate (ORR) by Independent Central Review (ICR) — 33; 0 Participants